These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
118 related articles for article (PubMed ID: 33390149)
21. Systemic therapy of cholangiocarcinoma: From chemotherapy to targeted therapies. Schweitzer N; Vogel A Best Pract Res Clin Gastroenterol; 2015 Apr; 29(2):345-53. PubMed ID: 25966433 [TBL] [Abstract][Full Text] [Related]
22. Dramatic response to trastuzumab and paclitaxel in a patient with human epidermal growth factor receptor 2-positive metastatic cholangiocarcinoma. Law LY J Clin Oncol; 2012 Sep; 30(27):e271-3. PubMed ID: 22851567 [No Abstract] [Full Text] [Related]
23. Effective palliation of advanced cholangiocarcinoma with sorafenib: a two-patient case report. LaRocca RV; Hicks MD; Mull L; Foreman B J Gastrointest Cancer; 2007; 38(2-4):154-6. PubMed ID: 19089671 [TBL] [Abstract][Full Text] [Related]
24. [Medical management of cholangiocarcinomas in 2015]. Marret G; Neuzillet C; Rousseau B; Tournigand C Bull Cancer; 2016 Apr; 103(4):389-99. PubMed ID: 26922666 [TBL] [Abstract][Full Text] [Related]
25. Comparison of resection and transarterial chemoembolisation in the treatment of advanced intrahepatic cholangiocarcinoma--a single-center experience. Scheuermann U; Kaths JM; Heise M; Pitton MB; Weinmann A; Hoppe-Lotichius M; Otto G Eur J Surg Oncol; 2013 Jun; 39(6):593-600. PubMed ID: 23611755 [TBL] [Abstract][Full Text] [Related]
26. Treatment of advanced intrahepatic cholangiocarcinoma with sintilimab combined with tegafur-gimeracil-oteracil potassium capsules (S-1): a case report. Liu J; Wang C; Cao L; Li S Ann Palliat Med; 2020 Mar; 9(2):497-503. PubMed ID: 32233637 [TBL] [Abstract][Full Text] [Related]
27. Arterial chemotherapy and conformal radiation abolish malignant biliary obstruction. Guan YS; Qing He ; Ping Li ; Fu YC; Zhao SW Integr Cancer Ther; 2008 Mar; 7(1):51-3. PubMed ID: 18292595 [TBL] [Abstract][Full Text] [Related]
28. Time to move to targeted drugs in biliary tract cancer? Louvet C; Tournigand C Onkologie; 2010; 33(1-2):10-1. PubMed ID: 20164655 [No Abstract] [Full Text] [Related]
29. Systemic therapy for hepatocellular carcinoma and cholangiocarcinoma. Chung V Surg Oncol Clin N Am; 2015 Jan; 24(1):187-98. PubMed ID: 25444475 [TBL] [Abstract][Full Text] [Related]
30. Prolonged Response to Anti-PD-1 Antibody Therapy in Chemotherapy-Refractory Cholangiocarcinoma With High Tumor Mutational Burden. Gbolahan O; Hashemi-Sadraei N; O'Neil B J Natl Compr Canc Netw; 2019 Jun; 17(6):644-648. PubMed ID: 31200359 [TBL] [Abstract][Full Text] [Related]
31. Neoadjuvant vs. adjuvant chemotherapy for cholangiocarcinoma: A propensity score matched analysis. Yadav S; Xie H; Bin-Riaz I; Sharma P; Durani U; Goyal G; Borah B; Borad MJ; Smoot RL; Roberts LR; Go RS; McWilliams RR; Mahipal A Eur J Surg Oncol; 2019 Aug; 45(8):1432-1438. PubMed ID: 30914290 [TBL] [Abstract][Full Text] [Related]
32. Successful response to the combination of immunotherapy and chemotherapy in cholangiocarcinoma with high tumour mutational burden and PD-L1 expression: a case report. Mou H; Yu L; Liao Q; Hou X; Wu Y; Cui Q; Yan N; Ma R; Wang L; Yao M; Wang K BMC Cancer; 2018 Nov; 18(1):1105. PubMed ID: 30419854 [TBL] [Abstract][Full Text] [Related]
33. Efficacy of hepatic arterial infusion chemotherapy using 5-fluorouracil and systemic pegylated interferon α-2b for advanced intrahepatic cholangiocarcinoma. Kasai K; Kooka Y; Suzuki Y; Suzuki A; Oikawa T; Ushio A; Kasai Y; Sawara K; Miyamoto Y; Oikawa K; Takikawa Y Ann Surg Oncol; 2014 Oct; 21(11):3638-45. PubMed ID: 24817369 [TBL] [Abstract][Full Text] [Related]
34. Combining biological agents and chemotherapy in the treatment of cholangiocarcinoma. Jensen LH; Jakobsen A Expert Rev Anticancer Ther; 2011 Apr; 11(4):589-600. PubMed ID: 21504326 [TBL] [Abstract][Full Text] [Related]
35. Clinical presentation and management of intrahepatic cholangiocarcinoma. Farges O; Fuks D Gastroenterol Clin Biol; 2010 Mar; 34(3):191-9. PubMed ID: 20202770 [No Abstract] [Full Text] [Related]
36. Targeted sequencing and molecular profiling of a papillary and cribriform clear cell intrahepatic cholangiocarcinoma reveals absence of selectable mutations. Aldecoa I; Montironi C; Vargas GM; Nunes DA; Miquel R; Cuatrecasas M Gastroenterol Hepatol; 2019; 42(6):374-375. PubMed ID: 30293915 [No Abstract] [Full Text] [Related]
37. How to schedule VEGF and PD-1 inhibitors in combination cancer therapy? Lai X; Friedman A BMC Syst Biol; 2019 Mar; 13(1):30. PubMed ID: 30894166 [TBL] [Abstract][Full Text] [Related]
38. [Prophylactic portal vein stenting in a patient with local recurrence of cholangiocarcinoma without clinical symptoms of portal vein stenosis - a case report]. Suzuki T; Takayashiki T; Shimizu H; Ohtsuka M; Kato A; Yoshitomi H; Furukawa K; Takano S; Kuboki S; Okamura D; Suzuki D; Sakai N; Kagawa S; Miyazaki M Gan To Kagaku Ryoho; 2014 Nov; 41(12):1536-8. PubMed ID: 25731244 [TBL] [Abstract][Full Text] [Related]
39. gamma-Aminobutyric acid inhibits cholangiocarcinoma growth by cyclic AMP-dependent regulation of the protein kinase A/extracellular signal-regulated kinase 1/2 pathway. Fava G; Marucci L; Glaser S; Francis H; De Morrow S; Benedetti A; Alvaro D; Venter J; Meininger C; Patel T; Taffetani S; Marzioni M; Summers R; Reichenbach R; Alpini G Cancer Res; 2005 Dec; 65(24):11437-46. PubMed ID: 16357152 [TBL] [Abstract][Full Text] [Related]
40. Feasibility and safety of long-term photodynamic therapy (PDT) in the palliative treatment of patients with hilar cholangiocarcinoma. Höblinger A; Gerhardt T; Gonzalez-Carmona MA; Hüneburg R; Sauerbruch T; Schmitz V Eur J Med Res; 2011 Sep; 16(9):391-5. PubMed ID: 22024438 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]